ByteDance has raised $290 million for its artificial intelligence drug-discovery business after spinning the unit out of the Chinese internet giant, giving the fledgling company a $1.5 billion valuation and providing fresh capital for its expansion.
Shanghai-based Anew Labs completed its first external fundraising round, two people familiar with the matter told Reuters. The financing was led by HSG, formerly known as Sequoia China, IDG Capital and Hillhouse Investment, alongside 5Y Capital as a co-lead investor.
Other investors included Gaorong Ventures, Primavera Venture Partners and Boyu Capital, as well as strategic investor SBP Group and the state-backed Shanghai Future Industries Fund, the sources said. They spoke on condition of anonymity because the information has not been made public.
Register for the next Tekedia Mini-MBA.
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
The financing marks a significant step for a company that was only recently separated from one of China’s largest technology groups. Anew Labs uses AI in drug discovery, a field where technology companies and investors are increasingly betting that machine learning can accelerate the identification of drug candidates and reduce some of the time and cost associated with conventional pharmaceutical research.
Anew Labs’ $1.5 billion valuation gives the business a substantial standalone market value despite its short history as an externally financed company. The fundraising also provides a new ownership structure under which ByteDance will retain a 56% stake, according to one of the sources.
The decision to spin out the unit reflects the different economics and operating requirements of AI drug discovery compared with ByteDance’s core internet businesses.
One source said ByteDance separated the AI drugmaker to better support its long-term development because AI-driven drug discovery follows a different industry logic and requires a different management approach from the group’s core operations.
Consumer internet businesses can often scale software products rapidly once they gain users, while drug discovery operates on a much longer development cycle and requires significant investment before commercial returns can emerge.
AI drug discovery also sits at the intersection of two capital-intensive industries. The technology requires substantial computing resources and specialized scientific talent, while successful drug development ultimately requires laboratory research, validation and, depending on the program, lengthy clinical development.
The new funding therefore gives Anew Labs the financial runway to develop its technology independently while retaining ByteDance as a majority shareholder.
ByteDance Builds an AI Portfolio Beyond Consumer Internet
The deal illustrates how Chinese technology companies are increasingly exploring AI applications outside the consumer products that made them global businesses.
ByteDance remains best known for TikTok and its Chinese counterpart Douyin, but the company has invested heavily in artificial intelligence across areas including foundation models, applications and infrastructure. Spinning out Anew Labs allows it to maintain exposure to another potentially valuable AI market while giving the drug-discovery business access to outside investors with expertise and capital specific to the sector.
The investor lineup is notable because it combines major Chinese venture and private-equity firms with a state-backed fund and a strategic investor.
That mix could provide Anew Labs with access to both financial resources and industry networks as it develops its technology. It also highlights the broader interest in AI as China seeks applications that extend beyond consumer-facing chatbots and into scientific research and industrial sectors.
The $1.5 billion valuation, however, should not be interpreted as evidence that AI has already transformed the economics of drug development. Drug discovery remains a high-risk business in which technical advances do not necessarily translate into successful medicines.
The value of an AI drug-discovery company ultimately depends on whether its models can identify promising compounds more efficiently, improve the probability of successful development, and translate those discoveries into commercially viable treatments. That makes the distinction between AI capability and pharmaceutical outcomes particularly important.
Anew Labs is entering a market where the potential payoff from successful drug candidates can be substantial, but where timelines are measured in years rather than the rapid product cycles common in consumer technology. The company’s ability to turn its AI capabilities into validated drug candidates will therefore matter more than the size of its initial funding round.
For ByteDance, retaining 56% means the company continues to have significant exposure to that upside while sharing the financing burden and bringing external investors into the business.
The structure could also give Anew Labs greater independence in attracting talent and capital. AI drug discovery requires expertise spanning machine learning, computational biology, chemistry, and pharmaceutical development, making it different from the engineering and product-management structures associated with ByteDance’s core platforms.
The fundraising is therefore as much about corporate structure as it is about capital.
ByteDance has effectively created a standalone vehicle through which investors can finance an AI application with a distinct development cycle, while the parent company preserves majority control.
For the wider Chinese AI industry, the deal adds to evidence that investment is moving beyond general-purpose models toward specialized applications where AI can potentially create value in sectors with high research costs.